Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SCOLR hits “milestone”

This article was originally published in The Tan Sheet

Executive Summary

Bellevue, Wash.-based firm SCOLR Pharma announces Sept. 26 that it has achieved a "milestone" in its development and license agreement with Wyeth Consumer Healthcare, which will result in a payment from Wyeth. SCOLR expects to report the payment as "research and development revenues" for the quarter ended Sept. 30. In the original December 2005 agreement, SCOLR granted Wyeth the worldwide rights to utilize SCOLR's patented Controlled Delivery Technology for potential use in an OTC formulations, according to the firm...

You may also be interested in...

SCOLR May File NDA For Ibuprofen Product Following Break With Wyeth

SCOLR Pharma will either file an NDA with FDA or work with another pharmaceutical company to develop its 12-hour extended-release ibuprofen product after Wyeth announced it will terminate an agreement with the firm effective April 16

The Good, The Bad And The Ugly Of COVID-19 Vaccine Manufacturing Technology Platforms

Not all technology platforms provide the expected benefit of filling in CMC review gaps and speeding coronavirus vaccine approvals.

SparingVision Raises €44.5m For Mutation-Agnostic Eye Gene Therapy

A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts